

## **Background**

In 2014, the World Health Assembly approved the World Health Organization's (WHO) Post-2015 Global TB Strategy, which aims to end the global TB epidemic by 2035 with an associated 95% decline in TB deaths, and a 90% decline in TB incidence. This strategy represents a unique and unprecedented opportunity to improve tuberculosis control in both high and low-incidence countries. TB control efforts will have to be dramatically intensified to meet the bold new goals. Innovations in care and prevention of TB have become part of a three pillar strategy that expands well beyond the traditional TB approach. A synergy of interventions from early case detection, to addressing the emergence of M(X)DR-TB needs to be addressed in order to achieve these targets.

The immensity of the challenges posed by the increasing emergence and uncontrolled spread of drug-resistant forms of TB underlines the failure of the status quo. Too many TB cases are neither diagnosed nor treated in time to avoid onward transmission. The treatment of MDR-TB patients using only existing anti-TB drugs has created an urgent unmet medical need. Low coverage of drug susceptibility testing (DST) in many countries and detection of drug resistance remains a major challenge. According to the WHO 2012 report only 94,000 cases of drug-resistant TB were identified. This indicates that the vast majority of patients went undiagnosed and could not be treated according to internationally recognized standards. The need for accurate diagnosis of TB and rapid detection of drug-resistance are critical to ensure timely initiation of treatment. The TB community has waited a long time for new MDR-TB medications and to ensure patients do not develop resistance to the new drugs better TB control practices have to be adapted.

This year the TB expert's community meeting will be "**Addressing the many faces of TB prevention in Asia**".

**Overarching goal:** Provide a forum for international discussion and development of a consensus statement of action needed to achieve unified and consistent standards for TB screening and prevention from the Asian TB experts community.

## **Objectives:**

1. Create a forum for the presentation and discussion of:
  - A. The importance of early diagnosis of tuberculosis including universal drug-susceptibility testing, and systematic screening of contacts and high-risk groups
  - B. Treatment of all people with Tuberculosis including drug resistant tuberculosis and patient support
2. Determine a regional best practise approach for the adaption on new LTBI guidelines.

**Format:** Symposium combining presentations and breakout discussions leading to concrete common statement of action

**Disclaimer:** This meeting is made possible by the provision of an unrestricted grant to Stop TB Japan by Otsuka, Sanofi- Aventis and Qiagen.

**Date:** August 7<sup>th</sup> – 9<sup>th</sup> 2015

**Location:** Bali, Indonesia

*“Addressing the Many faces of TB Prevention in Asia”*

Chaired by: Toru Mori, MD, PhD, Executive Representative, Stop TB Partnership Japan, Director Emeritus, Research Institute Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA)

Co- Chair: Erlina Burhan, MD?

Friday 7 <sup>th</sup> August		Location
19:00- 21:30	Welcome reception Canapés and Cocktails	TBD

Saturday 8th August	Topic	Speaker Name
09:00 – 09:15	Welcome, introductions and review of the agenda, Introductions	Toru Mori, MD
09:15 – 10:00	WHO – Keynote speech  Post- 2015 TB elimination strategy- A vision for Asia.	Mario Raviglione or  Nobuyuki Nishikiori or  Alberto Matteelli
10:00- 10:30	<b>Preventing TB Disease:</b> Improving the Diagnosis and Treatment of TB Infection	Chuck Daley, MD
10:30- 11:00	Break	
11:00-11:30	Presentation from Stop TB partnership	Lucica Ditiu, MD
11:30-12:00	Drug resistant TB	Ernesto Jaramillo, MD
12:00-12:30	Experiences in Indonesia: Optimization of the new MDR drug regimen	Christina Widaningrum, MD

12:30- 13:30	Lunch	
13:30-14:00	Introduction of new drug regimens in high M(X)DR countries	Rosalind G. Vianzon, MD
14:00-14:30	Putting Bi-directional TB and Diabetes screening into action	Dyah Erti Mustikawati
14:30-15:00	Rifapentine in Asia	TBA
15:00-15:30	Break	
15:30-16:00	China:	
16:00-16:30	India ?	Soumya Swaminathan, MD
16:30-17:00	Japan ?	TBA

Sunday 9 <sup>th</sup> August		
9:00-9:15	Welcome and review of the day 1 program,	
9:15-9:30	Introduction to structured discussion	
9:30- 10:30	<u>Structured Discussion</u>	Whole group
10:30-11:00	Break	
11:00-12:00	<u>Group discussion &amp; presentations</u>	Whole group
12:00-12:15	Summary and wrap up	
12:15-12:30	Closing speech	Toru Mori, MD